PMID- 16883221
OWN - NLM
STAT- MEDLINE
DCOM- 20060831
LR  - 20170310
IS  - 0022-9040 (Print)
IS  - 0022-9040 (Linking)
VI  - 46
IP  - 6
DP  - 2006
TI  - [Early use of gemfibrozil in patients with non ST Elevation acute coronary 
      syndrome. Changes of markers of inflammation and von Willebrand factor].
PG  - 37-42
AB  - It is not known whether PPAR-alpha agonist gemfibrozil is able to exert rapidly 
      its lipid modulating, potential antiinflammatory and antithrombotic effects in 
      patients with non-ST elevation acute coronary syndrome (NSTEACS), as some other 
      lipid lowering drugs e.g. statins do. METHODS: We randomized 44 patients with 
      NSTEACS to open gemfibrozil (n=22, 600 mg b.i.d for 90 days) or no gemfibrozil 
      (controls, n=22) within 24 hours after pain onset. Semiquantitative C-reactive 
      protein (CRP) latex test was used at baseline for exclusion of patients with 
      overt inflammation. All patients received dalteparin or enoxaparin for >48 hours 
      and oral aspirin (125 mg/day) and were treated noninvasively. Lipids, high 
      sensitive CRP, soluble CD40 ligand (CD40L) and von Willebrand factor (vWF) 
      activity were assessed on days 1 (baseline), 4, 7, 14, 30 and (except CD40L) 90. 
      RESULTS: Gemfibrozil use was associated with significant lowering of 
      triglycerides by day 30, however it did not prevent acute significant decline of 
      high density lipoprotein cholesterol (HDL-C), which was similar in both groups. 
      CD40L level significantly increased while CRP levels decreased by day 30 in both 
      groups. Moreover, selection of a subgroup with baseline HDL-C <1.0 mmol/l did not 
      reveal any difference in changes of CRP or CD40L between gemfibrosil treated and 
      control patients. vWF activity did not change in controls and significantly 
      increased in gemfibrozil group by days 7, 14, but from lower baseline level. 
      CONCLUSION: In patients with NSTEACS early administration of gemfibrozil was not 
      associated with positive changes of CRP and CD40L levels or vWF activity compared 
      with control group.
FAU - Vaulin, N A
AU  - Vaulin NA
AD  - Research Institute for Physicochemical Medicine; ul. Malaya Pirogovskaya 1a, 
      119828 Moscow, Russia.
FAU - Pokrovskaia, E V
AU  - Pokrovskaia EV
FAU - Deev, A D
AU  - Deev AD
FAU - Gratsianskii, N A
AU  - Gratsianskii NA
LA  - rus
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Russia (Federation)
TA  - Kardiologiia
JT  - Kardiologiia
JID - 0376351
RN  - 0 (Biomarkers)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (von Willebrand Factor)
RN  - 147205-72-9 (CD40 Ligand)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - Q8X02027X3 (Gemfibrozil)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Biomarkers/blood
MH  - C-Reactive Protein/*metabolism
MH  - CD40 Ligand/*blood
MH  - Coronary Disease/blood/*drug therapy/physiopathology
MH  - *Electrocardiography
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Follow-Up Studies
MH  - Gemfibrozil/*therapeutic use
MH  - Humans
MH  - Hypolipidemic Agents/*therapeutic use
MH  - Inflammation/blood
MH  - Male
MH  - Severity of Illness Index
MH  - Syndrome
MH  - Treatment Outcome
MH  - von Willebrand Factor/*metabolism
EDAT- 2006/08/03 09:00
MHDA- 2006/09/01 09:00
CRDT- 2006/08/03 09:00
PHST- 2006/08/03 09:00 [pubmed]
PHST- 2006/09/01 09:00 [medline]
PHST- 2006/08/03 09:00 [entrez]
PST - ppublish
SO  - Kardiologiia. 2006;46(6):37-42.